Hartline Investment Corp’s Moderna MRNA Stock Holding History

Hartline Investment Corp’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,691	Closed	-$287K	–	308
2024 Q1	$287K	Buy	+2,691	New	+$271K	0.05%	293

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Hartline Investment Corp's MRNA Position: Q2 2024 in Review

Hartline Investment Corp sold out of Moderna (MRNA) in Q2 2024, closing a stake of 2,691 shares — an estimated $287K sold.

Hartline Investment Corp first reported a position in MRNA in Q1 2024 and held it in 1 quarter. The position peaked at $287K in Q1 2024. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

Hartline Investment Corp reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
Hartline Investment Corp sold 2,691 Moderna shares in Q2 2024, an estimated $287K.
Hartline Investment Corp first reported a position in Moderna in Q1 2024 and held it in 1 quarter.
Hartline Investment Corp's Moderna position peaked at $287K in Q1 2024.
954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Hartline Investment Corp's 13F filing for Q2 2024, filed 9 Aug 2024.